Adjuvant immunotherapy in patients with high‐risk muscle‐invasive urothelial carcinoma: The potential impact of informative censoring-Reference-Cited by-同舟云学术

Adjuvant immunotherapy in patients with high‐risk muscle‐invasive urothelial carcinoma: The potential impact of informative censoring

Published:2022-05-12 Issue:15 Volume:128 Page:2892-2897
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Martini Alberto¹^ORCID,Yu Menggang²,Raggi Daniele³,Joshi Himanshu⁴^ORCID,Fallara Giuseppe¹^ORCID,Montorsi Francesco¹,Necchi Andrea³^ORCID,Galsky Matthew D.⁵

Affiliation:

1. Department of Urology Vita‐Salute San Raffaele University Milan Italy

2. Department of Biostatistics and Medical Informatics University of Wisconsin Madison Wisconsin

3. Department of Oncology Vita‐Salute San Raffaele University Milan Italy

4. Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai New York New York

5. Division of Hematology/Oncology Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York New York

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34255

Reference24 articles.

1. The natural history of untreated muscle-invasive bladder cancer

2. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer

3. National Comprehensive Cancer Network.Bladder Cancer. Version 3.2021. Published 2021. Accessed August 17 2021.https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

4. European Association of Urology.Muscle‐Invasive and Metastatic Bladder Cancer. Published 2021. Accessed August 17 2021.https://uroweb.org/guideline/bladder‐cancer‐muscle‐invasive‐and‐metastatic/

5. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Checkpoint Inhibitors in Urothelial Carcinoma—Future Directions and Biomarker Selection;European Urology;2023-11

2. Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer;The Lancet Oncology;2023-10

3. Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial;Urologic Oncology: Seminars and Original Investigations;2023-08

4. The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis;Clinical Genitourinary Cancer;2023-06

5. Impact of Age at Diagnosis of Bladder Cancer on Survival: A Surveillance, Epidemiology, and End Results-Based Study 2004-2015;Cancer Control;2023-01-20